|
|
|
Medical Aesthetics |
| |
Histogen Aesthetics is Created to
Address Growing Medical Aesthetics Market
Other Topics: Hospital
Data Transfer,
Neuroscience Software Tools
PRWEB
October 20, 2008
Dr. Lawrence A. Rheins Joins Histogen Aesthetics as President
San Diego/Phoenix - Histogen, Inc., a regenerative medicine
company developing solutions based on the products of newborn
dermal fibroblasts, today announced the creation of Histogen
Aesthetics LLC, a venture developing products for the growing
medical aesthetic industries based on Histogen's core
technology.
|
| |
|
|
| |
From a proprietary
bioreactor process in which newborn fibroblasts are grown under
proprietary embryonic-like conditions, Histogen Aesthetics
extracts a unique complex - ReGenicaTM - made up of the
naturally secreted growth factors, antioxidants and other
synergistic bio-products that are produced. This complex will
become the active ingredient in the Histogen Aesthetics line of
products for skin, hair and nail care.
The market for next generation, novel cosmeceuticals is rapidly
evolving, including the movement of physician-dispensed,
non-prescription products beyond the traditional medical
specialties of plastic surgery and cosmetic dermatology, and
into other medical specialties
There is a continuing need for adjunct palliative skin
conditioning products for use following all sorts of minimally
and more invasive cosmetic procedures - laser, dermabrasion - by
physicians engaged in aesthetic medicine.
Of the numerous products on the market, few have robust
controlled scientific data to support claims of clinical
improvement
Our goal is to create a line of skin, hair and nail care
products that are not only sensorially appealing to consumers,
but are based on the proven results of controlled clinical
studies. I am excited to announce the creation of Histogen
Aesthetics, and look forward to the launch of our first skin
care products for the physician-dispensed medical aesthetics
arena.
A recent clinical study of 49 patients, in which ReGenica was
used as a treatment following an ablative cosmetic laser
procedure, revealed improvement of overall skin condition in
comparison to the vehicle control. Histogen Aesthetics is
beginning follow-up studies of ReGenica for post-laser
resurfacing, as well as topical skin and hair anti-aging
applications.
Dermatology, cosmetics and biotechnology industry veteran
Lawrence A. Rheins, Ph.D. has joined Histogen Aesthetics, LLC as
President.
"The market for next generation, novel cosmeceuticals is rapidly
evolving, including the movement of physician-dispensed,
non-prescription products beyond the traditional medical
specialties of plastic surgery and cosmetic dermatology, and
into other medical specialties," said Rheins. "There is a
continuing need for adjunct palliative skin conditioning
products for use following all sorts of minimally and more
invasive cosmetic procedures - laser, dermabrasion - by
physicians engaged in aesthetic medicine."
Based on Histogen Aesthetics' initial studies, the Company
believes that the proteins and growth factors within ReGenica
work synergistically with the skin and hair's own physiology to
combat the effects of the normal aging process, making the
complex ideal for a breadth of advanced aesthetic products.
"Of the numerous products on the market, few have robust
controlled scientific data to support claims of clinical
improvement," continued Rheins. "Our goal is to create a line of
skin, hair and nail care products that are not only sensorially
appealing to consumers, but are based on the proven results of
controlled clinical studies. I am excited to announce the
creation of Histogen Aesthetics, and look forward to the launch
of our first skin care products for the physician-dispensed
medical aesthetics arena."
Dr. Rheins joins Histogen Aesthetics from the cosmetic/personal
care industry, and brings a rich, varied background in research
dermatology, tissue engineering and contract research clinical
services. Most recently, he served as Vice President of Science
and Technology at Floratech International, a raw material
supplier of botanical-derived ingredients for the cosmetic and
personal care industries. Prior to this, Dr. Rheins founded
DermTech International; a biotechnology company focused on
dermatologic, "point of care" diagnostics, and was co-inventor
of the Company's proprietary Epidermal Genetic Information
Retrieval (EGIR) technology.
Dr. Rheins was also previously Executive Director at Advanced
Tissue Sciences, a tissue engineering company focused on the
growth of human skin and other tissues. He served as Director of
pre-clinical/clinical CRO services at Hill Top Research, and
Divisional Toxicologist and Skin Laboratory Manager with Procter
& Gamble. Prior to his industry career, Dr. Rheins served as
Assistant Professor of Dermatology, at the University of
Cincinnati, College of Medicine. Dr. Rheins holds several
patents, and has authored more than 50 articles and book
chapters on immunology, toxicology, dermatology and in vitro
alternatives.
Histogen Aesthetics is currently focusing on the development of
the ReGenica line of products, with launches beginning in the
first quarter of 2009. These products will be distributed
through Secure Medical, a technology and health care solutions
provider based in Tempe, Arizona. Secure Medical already
partners with Histogen to distribute its first product, the
BioNuesisTM Human Stem Cell Culturing Kit.
About Histogen
Histogen, launched in 2007, seeks to redefine regenerative
medicine by developing a series of high- value products without
the use of embryonic stem cells or animal products. Through
Histogen's proprietary bioreactors that mimic the embryonic
environment, newborn fibroblasts are encouraged to naturally
produce the vital proteins and growth factors from which the
Company has developed its rich product portfolio. Histogen has
two product families - ExceltrixTM, Histogen's human
Extracellular Matrix (ECM) and ReGenicaTM, Histogen's
proprietary liquid formula. For more information, please visit
www.histogeninc.com or www.histogenaesthetics.com.
About Secure Medical
Secure Medical is a privately held company based in Tempe,
Arizona. The company possesses ownership and interests in a
variety of business models, all related to the medical industry.
The following solutions are among those provided by Secure
Medical: medical processing and fulfillment services/call center
capabilities; telemedicine/telehealth services in conjunction
with the American Telemedicine Association; and patented medical
kiosk manufacturing/creation of associated software and
hardware. Secure Medical is a biotech industry partner with
Histogen, Inc. of San Diego, and its newest venture, Histogen
Aesthetics. Histogen provides products that are naturally
produced, for regenerative medicine and stem cell research.
|
| |
|
|
| |
|
|
